Pernix Therapeutics Holdings Inc (PTX.OQ) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pernix Therapeutics Holdings Inc updates FY 2014 EBITDA outlook; revenue outlook to a range in line with analysts' estimates; gives FY 2015 EBITDA outlook; revenue outlook below analysts' estimates


Wednesday, 20 Aug 2014 08:00am EDT 

Pernix Therapeutics Holdings Inc:Expects FY 2014 revenue to be in the range of $110 - $120 mln.Expects FY 2014 Adjusted EBITDA of $22 -$24 mln.Expects FY 2015 revenue will be about $230 mln.Expects FY 2015 adjusted EBITDA of about $95 mln.FY 2014 revenue of $116 mln - Thomson Reuters I/B/E/S.FY 2015 revenue of $214 mln - Thomson Reuters I/B/E/S.